Sort   by:  
 Page size 
Therapies currently in preclinical development for prion disease seek to lower prion protein (PrP) expression in the brain. Trials of such therapies are likely to rely on quantification of PrP in cerebrospinal fluid (CSF) as a pharmacodynamic biomarker and possibly as a trial endpoint. Studies using...
ORGANISM(S): Homo Sapiens Rattus Norvegicus Mus Musculus Macaca Fascicularis 
2019-11-19 | PXD014781 | panorama
Prion protein (PrP) concentration controls the kinetics of prion replication and is a genetically and pharmacologically validated therapeutic target for prion disease. In order to evaluate PrP concentration as a pharmacodynamic biomarker and assess its contribution to known prion disease risk factor...
ORGANISM(S): Homo Sapiens Rattus Norvegicus 
2022-02-28 | PXD031432 | panorama
Not available
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2015-04-03 | MSV000079097 | MassIVE
Not available
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2015-02-09 | MSV000079033 | MassIVE
Data from Massive, ID: MSV000078918. Experiment: Discovery_inPatient_IgY14_Supermix_depletion, PMI_Patient1, file: G20121012_PMI_P24_SMdepl_iTRAQ_basicRP_fr23.mzml. Published as part of Mol Cell Proteomics. 2015 Feb 27 . From the Abstract: {{i}} We have developed a novel plasma protein analysis pla...
ORGANISM(S): Homo_sapiens_viruses, Human 
IgY14/Supermix depletion, patient 4, iTRAQ
ORGANISM(S): Homo Sapiens (human) 
2015-12-31 | PAe005319 | PeptideAtlas
IgY14 only depletion, patient 1, iTRAQ
ORGANISM(S): Homo Sapiens (human) 
2015-12-31 | PAe005318 | PeptideAtlas
IgY14/Supermix depletion, patient 2, iTRAQ
ORGANISM(S): Homo Sapiens (human) 
2015-12-31 | PAe005317 | PeptideAtlas
IgY14/Supermix depletion, TMT6
ORGANISM(S): Homo Sapiens (human) 
2015-12-31 | PAe005316 | PeptideAtlas
IgY14/Supermix depletion, TMT10
ORGANISM(S): Homo Sapiens (human) 
2015-12-31 | PAe005315 | PeptideAtlas
Sort   by:  
 Page size